Plasmid DNA CDMO Market Report 2025 (Global Edition)

Global Plasmid DNA CDMO Market Report 2025 Market Size Split by Type Outlook: (GMP Grade Plasmid DNA, Non-GMP Grade Plasmid DNA), by Application Outlook: (DNA Vaccines, Gene Therapy, Immunotherapy, Ot...

Plasmid DNA CDMO Market Report Description

We have various report editions of Plasmid DNA CDMO Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Plasmid DNA CDMO Market Insights Video

Competitive Landscape of the Plasmid DNA CDMO Market

The plasmid DNA CDMO market is characterized by intense competition among key players, including Lonza, WuXi AppTec, and Aldevron. These companies leverage advanced technologies and extensive experience in plasmid DNA production to cater to the growing demand in gene therapy and vaccine development

In June 2024, Bionova Scientific, a U.S.-based biologics CDMO under the Asahi Kasei Group, announced the establishment of a dedicated plasmid DNA facility in The Woodlands, Texas. This expansion aims to support the growing demand for cell and gene therapies by providing process development and GMP manufacturing services. Operations are scheduled to commence in early 2025, positioning Bionova to leverage Texas's expanding CGT ecosystem.
(Source -  https://www.asahi-kasei.com/news/2024/e240603.html )
 

Top Companies Market Share in Plasmid DNA CDMO Industry: (In no particular order of Rank)

• Charles River Laboratories
• VGXI
• Inc.
• Danaher (Aldevron)
• Kaneka Corp.
• Nature Technology
• Cell and Gene Therapy Catapult
• Eurofins Genomics
• Lonza
• Luminous BioSciences
• LLC
• Akron Biotech
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Plasmid DNA CDMO Market

Which Region Dominates the Plasmid DNA CDMO Market in 2024?

According to Cognitive Market Research, North America currently dominates the Plasmid DNA CDMOs market, and the region is expected to increase demand for plasmid DNA in gene therapy, vaccine development, and synthetic biology applications. The region's advanced biotechnology infrastructure, alongside substantial investments in research and development, fosters innovation and production capabilities. Major pharmaceutical and biotechnology companies are collaborating with CDMOs to streamline the manufacturing process, ensuring quality and regulatory compliance. Additionally, the growing prevalence of genetic disorders and the rising number of clinical trials in gene therapies contribute to the market's expansion.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The increasing demand for advanced therapies such as gene therapy and vaccine development. Key factors include the rise in biopharmaceutical companies focusing on innovative treatments, coupled with supportive government initiatives to boost biotechnology sectors. Countries like China, Japan, and India are at the forefront, leveraging their expanding biomanufacturing capabilities and skilled workforce. The presence of a large patient population and rising investments in research and development further contribute to market growth. Additionally, collaborations between local firms and global players are enhancing technological advancements and production efficiencies.

The current report Scope analyzes Plasmid DNA CDMO Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Plasmid DNA CDMO Market Analysis

According to Cognitive Market Research, the global Plasmid DNA CDMO Market size was estimated at USD 275.9 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 110.36 million in 2024 and will grow at a compound annual growth rate (CAGR) of 18.7% from 2024 to 2031.

• According to Cognitive Market Research, the U.S. had a major share in the Plasmid DNA CDMO Market with a market size of USD 87.07 million in 2024 and is projected to grow at a CAGR of 18.5% during the forecast period. Regulatory support for advanced therapies and increased investment in R&D also bolster demand for specialized CDMO services.
• The Canada Plasmid DNA CDMO Market had a market share of USD 13.25 million in 2024 and is projected to grow at a CAGR of 19.5% during the forecast period. Canada’s strong infrastructure for clinical research and regulatory support for biotech advancements also make it a favorable environment for CDMOs.
• The Mexico Plasmid DNA CDMO Market is projected to witness growth at a CAGR of over 19.2% during the forecast period, with a market size of USD 10.04 million in 2024.

Europe Plasmid DNA CDMO Market Analysis

According to Cognitive Market Research, the global Plasmid DNA CDMO Market size was estimated at USD 275.9 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 82.77 million in 2024 and will grow at a compound annual growth rate (CAGR) of 19.0% from 2024 to 2031.

• The United Kingdom Plasmid DNA CDMO Market had a market share of USD 13.91 million in 2024 and is projected to grow at a CAGR of 19.8% during the forecast period. Plasmid DNA UK’s strong biopharma infrastructure and government support for biotech innovations further fuel market growth..
• The France Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 18.2% during the forecast period, with a market size of USD 7.61 million in 2024.
• According to Cognitive Market Research, the German Plasmid DNA CDMO Market size was valued at USD 16.39 million in 2024 and is projected to grow at a CAGR of 19.2% during the forecast period. In Germany, Plasmid DNA CDMO increasing prevalence of genetic disorders and chronic diseases creates demand for innovative therapeutics, fueling the need for plasmid DNA.
• The Italy Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 119.9% during the forecast period, with a market size of USD 7.12 million in 2024.
• The Russia Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 21.4% during the forecast period, with a market size of USD 12.83 million in 2024.
• The Spain Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 18.1% during the forecast period with a market size of USD 6.79 million in 2024
• The Luxembourg Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 19.1% during the forecast period, with a market size of USD 2.57 million in 2024.
• The Portugal Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 18.8% during the forecast period, with a market size of USD 1.74 million in 2024.
• The Greece Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 19.3% during the forecast period, with a market size of USD 0.99 million in 2024.
• The Rest of Europe's Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 17.7% during the forecast period, with a market size of USD 12.83 million in 2024.

Asia Pacific Plasmid DNA CDMO Market Analysis

According to Cognitive Market Research, the global Plasmid DNA CDMO Market size was estimated at USD 275.9 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 63.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 22.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Plasmid DNA CDMO Market size was valued at USD 28.56 million in 2024 and is projected to grow at a CAGR of 22.0% during the forecast period. Plasmid DNA CDMO China's expanding healthcare infrastructure, along with government support for the biotechnology sector, fosters a conducive environment for the market.
• The Japan Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 21.0% during the forecast period, with a market size of USD 20.26 million in 2024.
• The India Plasmid DNA CDMO Market had a market share of USD 7.61 million in 2024 and is projected to grow at a CAGR of 24.3% during the forecast period. India's strong pharmaceutical manufacturing infrastructure, coupled with a skilled workforce, has made it an attractive destination for global pharmaceutical companies seeking cost-effective production solutions.
• The South Korean Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 10.1% during the forecast period, with a market size of USD 21.6 million in 2024.
• The Australian Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 22.2% during the forecast period, with a market size of USD 3.30 million in 2024.
• The South East Asia Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 23.5% during the forecast period, with a market size of USD 4.38 million in 2024.
• The Rest of the Asia Pacific Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 22.3% during the forecast period, with a market size of USD 4.51 million in 2024.

South America Plasmid DNA CDMO Market Analysis

According to Cognitive Market Research, the global Plasmid DNA CDMO Market size was estimated at USD 275.9 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 13.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 19.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Plasmid DNA CDMO Market size was valued at USD 5.90 million in 2024 and is projected to grow at a CAGR of 20.5% during the forecast period. Plasmid DNA CDMOs Brazil's robust healthcare infrastructure and growing biotech industry make it an attractive market for plasmid DNA CDMOs.
• Argentina's Plasmid DNA CDMO Market had a market share of USD 2.32 million in 2024 and is projected to grow at a CAGR of 20.8% during the forecast period. Argentina's cost-efficient manufacturing capabilities are another significant factor fueling the market.
• Colombia Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 19.7% during the forecast period, with a market size of USD 1.23 million in 2024.
• Peru Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 20.1% during the forecast period, with a market size of USD 1.13 million in 2024.
• Chile Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 20.2% during the forecast period, with a market size of USD 0.99 million in 2024.
• The Rest of Latin America's Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 19.0% during the forecast period, with a market size of USD 2.22 million in 2024.

Middle East Plasmid DNA CDMO Market Analysis

According to Cognitive Market Research, the global Plasmid DNA CDMO Market size was estimated at USD 275.9 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 5.52 million in 2024 and will grow at a compound annual growth rate (CAGR) of 20.2% from 2024 to 2031..

• The GCC Countries Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 21.0% during the forecast period, with a market size of USD 2.36 million in 2024. Plasmid DNA CDMO's rising prevalence of chronic diseases, along with improved regulatory frameworks, is expected to fuel the market growth.
• The Egypt Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 20.5% during the forecast period, with a market size of USD 0.58 million in 2024.
• The South Africa Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 21.2% during the forecast period, with a market size of USD 0.87 million in 2024. Plasmid DNA CDMO Government initiatives and investments in the healthcare infrastructure further support the market, encouraging partnerships between local and international CDMOs.
• The Turkey Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 19.7% during the forecast period, with a market size of USD 0.47 million in 2024.
• The Nigeria Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 19.7% during the forecast period, with a market size of USD 0.58 million in 2024.
• The Rest of the MEA Plasmid DNA CDMO Market is projected to witness growth at a CAGR of 19.2% during the forecast period, with a market size of USD 0.65 million in 2024.

Plasmid DNA CDMO Market Analysis

How are Segments Performing in the Global Plasmid DNA CDMO Market?

Plasmid DNA CDMO Market Type Segment Analysis

According to Cognitive Market Research, GMP (Good Manufacturing Practice) Grade Plasmid DNA is manufactured under stringent regulatory standards, ensuring its suitability for clinical and commercial applications, including gene therapy, vaccines, and advanced cell therapies. Due to its compliance with regulatory bodies such as the FDA and EMA, GMP-grade plasmid DNA is essential for therapeutic use, particularly where patient safety and product efficacy are paramount. Demand for GMP-grade plasmid DNA has been driven by growth in gene therapy and cell-based treatment research, as well as increased regulatory scrutiny on biologics production..

The Non-GMP Grade Plasmid DNA is typically produced for research purposes and early-phase development where regulatory compliance is less rigorous. This type is used primarily in preclinical studies, proof-of-concept research, and academic laboratories, allowing for faster and cost-effective production. The flexibility of non-GMP-grade production processes makes it more accessible for R&D activities, where companies and institutions require smaller volumes and cost-effective plasmid production..

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Plasmid DNA CDMO Industry. Request a Free Sample PDF!

Plasmid DNA CDMO Market Application Segment Analysis

According to Cognitive Market Research, the DNA Vaccines segment has gained significant traction due to the growing focus on developing effective vaccines against infectious diseases and certain cancers. DNA vaccines work by introducing plasmid DNA encoding antigens, prompting the body to generate a protective immune response. The COVID-19 pandemic accelerated interest in DNA vaccine production, as they promise quick scalability and stable storage conditions. Increasing government and private investments in vaccine R&D further propel demand within this segment, positioning DNA vaccines as a substantial growth driver in the plasmid DNA CDMO market.

In the Plasmid DNA CDMO Market, the gene therapy segment has emerged as a transformative area in precision medicine. Gene therapy uses plasmid DNA to deliver therapeutic genes to correct or mitigate the effects of genetic disorders, cancers, and other serious health conditions. The demand for high-quality plasmid DNA in gene therapies is driven by expanding clinical applications and advancements in genetic research. High regulatory standards and the need for efficient, scalable manufacturing processes have led to increased collaboration with CDMOs specializing in gene therapy plasmids, solidifying this segment's potential in the broader CDMO market..

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion